Abbott Laboratories (NYSE:ABT) shares traded on 1.67% above secure line and closed at $69.44. The stock exchanged hands 6.09 Million shares versus average trading capacity of 7.58 Million shares. It has a market cap of $124.45 Billion.
Wall Street analysts are predicting that Abbott Laboratories (NYSE:ABT) will report earnings per share of $0.81 in their quarterly report. For the current quarter Abbott Laboratories (NYSE:ABT) has high EPS estimates of $0.82 in contradiction of low EPS estimates of $0.8. However a year ago for the same quarter the company has reported $0.74 EPS. Average estimation for the current quarter has been provided by 21 analysts.
Investors as well as the sell-side will be paying close attention to how the actual numbers compare with the estimates. Earnings surprises can have a huge impact on a company’s stock price. Several studies suggest that positive earnings surprises not only lead to an immediate hike in a stock’s price, but also to a gradual increase over time. Hence, it’s not surprising that some companies are known for routinely beating earning projections. A negative earnings surprise will usually result in a decline in share price.
A large surprise factor in either direction typically can lead to a significant swing in the stock price in the hours and days after the report. Previously Abbott Laboratories (NYSE:ABT) reported $0.75 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.75 by $0 with surprise factor of 0%.
Abbott Laboratories (NYSE:ABT) has average revenue estimates of $7.82 Billion, compared to low analyst estimates of $7.7 Billion and high estimates of $7.92 Billion for the current quarter. A total number of 19 analysts provided estimations over revenues. For the current year the company’s revenue estimates are $30.66 Billion compared to low analyst estimates of $30.52 Billion and high estimates of $31.04 Billion according to the prediction of 21 analysts.
Taking a broader look at the analyst consensus, according to 19 analysts Abbott Laboratories (NYSE:ABT)’s price will reach at $79.58 during 52 weeks. Its minimum price target estimates has been figured out at $72 while the maximum price target forecast is established at $86.
On the other hand Abbott Laboratories (NYSE:ABT) has Relative Strength Index (RSI 14) of 48.49 along with Average True Range (ATR 14) of 2.26. Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock’s price movement. The RSI value will always move between 0 and 100; the value will be 0 if the stock falls on all 14 days, and 100, if the price moves up on all the days) as suggested by J Welles Wilder. In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. The level of 50 represents neutral market momentum and corresponds with the center line in other oscillators such as MACD (Moving Average Convergence/Divergence). The average true range (ATR) is a measure of volatility introduced by Welles Wilder.
Consequently Abbott Laboratories (NYSE:ABT)’s weekly and monthly volatility is 3.09%, 2.93% respectively.